Related by context. All words. (Click for frequent words.) 69 riociguat 68 CIMZIA TM 68 #mg BID [001] 67 CIMZIA ™ 67 MYDICAR ® 67 INCB# [001] 66 placebo controlled clinical 66 safinamide 66 mg kg dose 66 ACTEMRA TM 66 ProSavin 66 GAMMAGARD 66 ataluren 66 EDEMA3 trial 66 HuMax EGFr 65 brivaracetam 65 cortical stimulation 65 clinically meaningful improvements 65 teriflunomide 65 GSK# [001] 65 tocilizumab 65 Phase 2a trial 65 Capesaris 65 TEMSO 65 FOLPI 65 multicenter placebo controlled 65 clinically meaningful improvement 64 Phase IIB 64 phase IIb study 64 desvenlafaxine succinate 64 phase IIa 64 CIMZIA TM certolizumab pegol 64 apremilast 64 decitabine 64 Spheramine 64 glufosfamide 64 CYPHER Stent 64 SPIRIT FIRST 64 virologic response 64 CERE 64 EVIZON 64 NATRECOR R 64 complete cytogenetic response 64 STRIDE PD 64 dosing cohort 64 basal bolus regimen 64 efficacy endpoint 64 #mg dose [002] 64 ABSORB trial 63 APTIVUS r 63 IV NSCLC 63 placebo controlled Phase 63 GRN# 63 ancrod 63 phase IIa clinical 63 morphometric vertebral fractures 63 cannabinor 63 Unified Parkinson Disease 63 virological response 63 CTAP# Capsules 63 R# #mg BID 63 elotuzumab 63 Phase 1a clinical 63 HCV SPRINT 63 PREZISTA r 63 PRT# 63 Acute Ischemic Stroke 63 viral kinetics 63 eosinophilic asthma 63 RRMS patients 63 oral FTY# 63 pramipexole 63 Golimumab 63 canakinumab 63 Safinamide 63 HORIZONS AMI trial 63 Subgroup analysis 63 INCB# [003] 63 IFN α 63 Phase #/#a 63 MGd 63 AGILECT R 63 everolimus eluting stents 63 custirsen 63 ularitide 63 SERCA2a 63 CR# vcMMAE 63 CIPN 63 ximelagatran 63 peg interferon 63 PD LID 63 viral kinetic 63 ISIS # 62 PASI scores 62 neurologic progression 62 Phase 2b study 62 fosbretabulin 62 adalimumab 62 edifoligide 62 recurrent glioma 62 CINQUIL 62 metastatic RCC 62 MYDICAR 62 statistically significant efficacy 62 ACZ# 62 secondary efficacy endpoints 62 MERLIN TIMI 62 Traficet EN 62 evaluating tivozanib 62 tolvaptan 62 randomized blinded 62 recurrent glioblastoma multiforme 62 EchoCRT 62 TTF Therapy 62 omecamtiv mecarbil 62 dose escalation phase 62 CA4P 62 CLARITY study 62 Imprime PGG 62 BRIM2 62 Arikace 62 QTc prolongation 62 PSMA ADC 62 somatostatin analog 62 rosuvastatin #mg 62 binary restenosis 62 insulin degludec 62 chemoradiotherapy 62 #mg QD [001] 62 EGFR TKI 62 R#/MEM # 62 HCV RESPOND 2 62 standard chemotherapy regimen 62 colesevelam HCl 62 randomized Phase IIb 62 ADAGIO study 62 Bezielle 62 comparator arm 62 BRIM3 62 iroxanadine 62 bardoxolone methyl 62 RLAI 62 iniparib 62 cediranib 62 phase IIb trial 62 Phase Ib study 62 Ocrelizumab 62 CRLX# 62 Phase IIa trials 62 pomalidomide 62 BENICAR HCT 62 PS# [001] 62 antipsychotic efficacy 62 nab paclitaxel 62 urocortin 2 62 FOLFOX4 62 Catena ® 61 IR prednisone 61 angiographic outcomes 61 oxycodone CR 61 tarenflurbil 61 Pimavanserin 61 ACTEMRA 61 ganetespib 61 PROMACTA 61 Ophena TM 61 undetectable HBV DNA 61 active comparator 61 relapsing MS 61 tipranavir r 61 elagolix 61 lenalidomide dexamethasone 61 dapagliflozin plus 61 rotigotine 61 tapentadol ER 61 abiraterone acetate 61 weekly subcutaneous injections 61 GFT# 61 DAPT 61 GALNS 61 ATACAND 61 XIENCE V PROMUS Stent 61 phase Ib 61 ELACYT 61 EndoTAG TM -1 61 NEVO ™ 61 APOPTONE 61 Aflibercept 61 sustained virologic response 61 IIa trial 61 pharmacokinetic PK 61 Randomized Phase 61 Virulizin ® 61 clinical trials Multikine 61 Teriflunomide 61 Phase IIa trial 61 clinical pharmacology studies 61 Symadex 61 dose escalation Phase 61 Dacogen injection 61 anti leukemic 61 CBLC# 61 TG# [003] 61 sustained virological response 61 Ostarine 61 dose cohorts 61 carboplatin paclitaxel 61 bronchial thermoplasty 61 phase IIb clinical 61 Phase 2a clinical 61 intermittent dosing 61 alvimopan 61 symptomatic VTE 61 rTMS 61 mcg Albuferon 61 plus prednisone 61 Neurodex 61 RSD# oral 61 lixisenatide 61 diabetic neuropathic pain 61 dosing cohorts 61 LEXIVA r 61 dose cohort 61 TriRima 61 ADVANCE PD 61 multicenter Phase II 61 hyperphenylalaninemia HPA due 61 stage IIIB 61 prespecified secondary 61 PROactive study 61 Phase 2a 61 CCX# B 61 virologic responses 61 randomized #:#:# 61 IRX 2 61 TAXUS Stent 61 tanespimycin 61 adecatumumab 61 multicenter Phase 61 Amrubicin 61 MAGE A3 ASCI 61 NV1FGF 61 icatibant 61 subanalysis 61 complete cytogenetic 61 venlafaxine XR 61 pertuzumab 61 8mg/kg 61 OXi# 61 SNT MC# 61 CCX# 61 cinacalcet 61 Phase Ib clinical 61 eszopiclone 61 TMC# r 61 Tavocept 61 GRNCM1 61 glycated hemoglobin levels 61 KRN# 61 randomized Phase 2b 61 Androxal TM 61 mg/m2 cohort 61 PRECiSE 60 Plicera 60 rimonabant #mg 60 Sym# 60 rFVIIa 60 AeroLEF TM 60 Pharmacokinetic parameters 60 Microplasmin 60 NYHA functional class 60 metaglidasen 60 STN DBS 60 CTEPH 60 plus methotrexate 60 PRX # 60 CHAMPION PCI 60 IFN alfa 60 DACH platinum 60 alemtuzumab treated 60 evaluable subjects 60 postoperative chemotherapy 60 dose titration 60 velafermin 60 Mipomersen 60 RAPAFLO 60 recurrent NSCLC 60 oral rivaroxaban 60 TNF antagonist 60 trial evaluating PRX# 60 pegylated interferon alfa 2b 60 PROSTVAC TM 60 LHON 60 Phenoptin 60 dose proportionality 60 Ceplene/IL-2 60 Azedra 60 abatacept 60 pyridostigmine 60 doxorubicin docetaxel 60 PRX# 60 LVEF 60 certolizumab pegol 60 clinically meaningful 60 azacitidine 60 timepoint 60 flurpiridaz F 60 NTx TM -# 60 demonstrated clinically meaningful 60 EDSS scores 60 irbesartan 60 Phase #b/#a 60 mucosal healing 60 imatinib therapy 60 TORISEL 60 davunetide intranasal AL 60 HGS ETR1 60 elacytarabine 60 nitazoxanide 60 Free Survival PFS 60 baseline HbA1c 60 placebo controlled Phase III 60 ACAPODENE 60 phase IIIb 60 rindopepimut 60 alteplase 60 PEG Interferon lambda 60 refractory angina 60 prospective randomized placebo 60 sargramostim 60 NATRECOR ® 60 biochemical relapse 60 Cethrin 60 definite stent thrombosis 60 mg/m2 dose 60 AZILECT R 60 tumor necrosis 60 double blinded placebo 60 nonrandomized 60 intra articular injection 60 Hepatocellular Carcinoma HCC 60 metastatic renal cell carcinoma 60 MabCampath 60 ALA PDT 60 TAXUS Liberte Stent 60 YONDELIS 60 methotrexate monotherapy 60 Decitabine 60 VELCADE melphalan 60 pharmacokinetic PK study 60 NP2 Enkephalin 60 SYMMETRY trial 60 6R BH4 60 ChronVac C ® 60 motesanib 60 Alocrest 60 eltrombopag 60 Allovectin 7 ® 60 cytogenetic response 60 dopaminergic therapy 60 pegaptanib 60 RLY# 60 certolizumab 60 mcg BID 60 relapsed MM 60 ischemic cardiomyopathy 60 ILLUMINATE 60 VADT 60 chemoradiation therapy 60 interferon ribavirin 60 mapatumumab 60 ibandronate 60 PROCHYMAL 60 TIMP 1 60 Initiated Phase 60 calcineurin inhibitor 60 talactoferrin 60 OncoVEX GM CSF 60 vismodegib 60 glycosylated hemoglobin HbA1c 60 Chemophase 60 Inhaled AAT 60 dose escalation clinical 60 Cloretazine R VNP#M 60 SVR# 60 EXPAREL TM 60 serum uric acid sUA 60 QLT# 60 MACUGEN 60 ER CHOP 60 KNS # 60 EndoTAGTM 1 60 docetaxel chemotherapy 60 PEG SN# 60 AIR2 Trial 60 repetitive transcranial magnetic stimulation 60 Thal Dex 60 COPAXONE R 60 clinically meaningful reductions 60 Amplimexon 60 Cogane 60 GPi 60 darapladib 60 ZOLINZA 60 pegylated liposomal doxorubicin 60 Tolvaptan 60 synthetic retinoid 60 PEG PAL 60 ARCALYST ® 60 TroVax ® 59 registrational trial 59 bosentan 59 Triolex 59 MIRAPEX ER 59 adenotonsillectomy 59 FOLFIRI 59 achieved ACR# 59 fondaparinux 59 Amigal 59 TAXUS ATLAS 59 MVax 59 Ozarelix 59 placebo controlled dose escalation 59 O PPDS 59 FTY# 59 DDP# 59 Doxil ® 59 haematologic 59 Gabapentin GR 59 VIAject ™ 59 Natalizumab 59 VAPRISOL 59 Raptiva r 59 treatment naïve genotype 59 recurrent GBM 59 budesonide foam 59 Ophena 59 TRIOLEX 59 locoregional disease 59 TDF FTC 59 mGluR2 NAM 59 paliperidone ER 59 preclinically 59 intermittent claudication 59 resynchronization therapy 59 relapsing multiple sclerosis 59 RECIST Response Evaluation Criteria 59 statistically significant p = 59 Phase #b/#a trial 59 remyelination 59 GOUT 59 Valdoxan 59 sorafenib Nexavar 59 dexanabinol 59 ZYBRESTAT 59 pharmacodynamic effects 59 IPL# 59 rapid virologic response 59 clevidipine 59 ORMD 59 EXJADE 59 Vitaxin 59 secondary efficacy endpoint 59 XGEVA 59 CAMMS# 59 levosimendan 59 ACR# responses 59 sirolimus eluting stents 59 ruboxistaurin 59 intravascular hemolysis 59 phase 2a 59 BAY #-# 59 DASISION 59 sunitinib Sutent 59 CANCIDAS 59 ATL# [001] 59 hematologic toxicity 59 Zevalin consolidation 59 tgAAC# 59 mycophenolate mofetil 59 undetectable HCV RNA 59 APTIVUS 59 dirucotide 59 omega interferon 59 PEG IFN 59 prospective multicenter randomized 59 paclitaxel eluting stents 59 catheter occlusion 59 rt PA 59 Pegasys plus Copegus 59 sitaxsentan 59 baminercept 59 rilonacept 59 recurrent glioblastoma 59 Subgroup analyzes 59 CYT# potent vascular disrupting 59 Xelox 59 Castration Resistant Prostate Cancer 59 PTNS 59 SNT-MC#/idebenone 59 prospectively randomized 59 p# biomarker 59 NOX E# 59 plasma kallikrein inhibitor 59 crizotinib PF # 59 QTcF 59 favorable pharmacokinetic profile 59 gemcitabine carboplatin 59 Desmoteplase 59 blinded randomized placebo controlled 59 imexon 59 blinded randomized 59 aflibercept 59 azilsartan medoxomil 59 Carfilzomib 59 splenectomized 59 rFIXFc 59 COPERNICUS 59 PXD# 59 Phase IIa 59 Kaplan Meier analysis 59 hemoglobin A1c levels 59 alvespimycin 59 cilengitide 59 ReN# 59 prospectively defined 59 Dasatinib 59 bortezomib refractory 59 briakinumab 59 Archexin 59 cabazitaxel 59 docetaxel prednisone 59 Durezol 59 Neovascular AMD 59 achieved statistical significance 59 TRO# 59 valopicitabine 59 Phase Ib II 59 OPCAB 59 multicenter randomized controlled 59 pazopanib 59 maximally tolerated lipid lowering 59 ® natalizumab 59 Tamibarotene 59 vidofludimus 59 sunitinib 59 TBC# 59 dosage regimens 59 inotropic 59 Cimzia ® certolizumab pegol 59 efficacy endpoints 59 Degarelix 59 pharmacokinetic PK profile 59 EOquin TM 59 Aptivus ® 59 GEM OS1 59 refractory AML 59 LT NS# 59 posaconazole 59 TRAIL R1 59 stage IIIb IV 59 gastrointestinal toxicities 59 ADAS Cog 59 tDCS 59 nalbuphine ER 59 Vascugel 59 MP4OX 59 lenalidomide Revlimid R 59 oral allopurinol 59 DCCR 59 goserelin 59 DU #b 59 Granulocyte Colony Stimulating Factor 59 Pharmacokinetic studies 59 imetelstat 59 visilizumab 59 Phase IIa clinical 59 Phase 1b clinical trials 59 Meets Primary Endpoint 59 MCyR 59 Fludara 59 Lu AA# 59 trastuzumab Herceptin ® 59 treprostinil 59 MAP# 59 paricalcitol 59 CR nPR 59 Elitek 59 febuxostat 59 plasma pharmacokinetics 59 AVADO 59 BrachySil TM 59 teduglutide 59 tasimelteon 59 trials RCTs 59 atrasentan 59 zotarolimus eluting stent 59 mcg QD 59 mRCC 59 intravenous cyclophosphamide 59 ascending dose 59 SYN# 59 Thrombolysis 59 intracoronary 59 Actilon 59 urate lowering therapy 59 forodesine 59 ACR# response 58 ginkgo extract 58 samalizumab 58 HER2 positive metastatic breast 58 Eculizumab 58 HCV infected 58 GnRH agonist 58 relapsed myeloma 58 plus dexamethasone 58 intravitreal injection 58 Vectibix monotherapy 58 Zoraxel 58 Pharmacokinetic 58 fosamprenavir 58 Aplidin 58 pCR 58 RG# [001] 58 everolimus eluting stent 58 noninferiority 58 mCRC patients 58 OZURDEX ® 58 LUX Lung 58 PreCISe 58 pulmonary artery banding 58 primary patency 58 RoACTEMRA 58 secretin 58 peginterferon 58 F FDG PET 58 CEQ# 58 insulin detemir 58 triphendiol 58 Tyrima 58 PF # [001] 58 platelet reactivity 58 chlorambucil 58 cilostazol 58 clazosentan 58 double blinded randomized 58 oxymorphone ER 58 PRIMO CABG 58 preclinical efficacy 58 Non inferiority 58 BETAS 58 unstable angina pectoris 58 novel VDA molecule 58 abnormal p# biomarker 58 Phase IIIb clinical 58 SCIg 58 ARB telmisartan 58 lintuzumab 58 SYNTAX trial 58 PEGylated interferon beta 1a 58 enoximone 58 ocrelizumab 58 Elocalcitol 58 IPX# 58 EECP therapy 58 pain palliation 58 amrubicin 58 denufosol 58 oral ridaforolimus 58 Chrysalin 58 rFVIIIFc 58 RE LY ® 58 urate lowering 58 CORT # 58 celgosivir 58 evaluating REVLIMID 58 prospective multicenter study 58 EDEMA3 58 axitinib 58 iSONEP 58 PERSEUS 58 glomerular filtration 58 ADAS cog 58 AVOREN 58 interferon beta therapy 58 mitoxantrone plus 58 COPAXONE ® 58 orBec 58 Rezular 58 rapid virological response 58 Xanafide 58 transaminase elevations 58 RezularTM 58 exploratory endpoints 58 placebo dexamethasone 58 β blockers 58 serum phosphorous 58 pharmacodynamic PD 58 Omacetaxine 58 mg TID 58 Vernakalant 58 cisplatin vinorelbine 58 telaprevir dosed 58 HBeAg seroconversion 58 Vidaza azacitidine 58 serum clusterin levels 58 Zenvia Phase III 58 enzastaurin 58 mcg albinterferon alfa 2b 58 Epanova 58 neurogenic orthostatic hypotension 58 OMS# 58 sipuleucel T 58 HGS# 58 PegIFN RBV 58 avosentan 58 mGluR5 NAM 58 Diamyd r vaccine 58 bicifadine 58 liver histology 58 surrogate endpoint 58 UPDRS 58 dose melphalan 58 phase IIb 58 ribavirin RBV 58 genotype 1a 58 parkinsonian symptoms 58 trastuzumab emtansine T DM1 58 immunomodulation 58 HuMax CD# 58 E1 INT TM 58 eprotirome 58 LCP Tacro 58 methylnaltrexone 58 oral Xeloda 58 satraplatin Phase 58 lumiliximab 58 Apoptone 58 LY# [003] 58 HuLuc# 58 neoadjuvant chemotherapy 58 mg BID 58 dexpramipexole 58 Cetrorelix 58 ABC/3TC 58 TACI Ig 58 pramlintide 58 AVONEX ® 58 multicenter randomized placebo controlled 58 heterozygous FH 58 OvaRex MAb 58 paclitaxel poliglumex 58 clinically localized prostate 58 ULORIC 58 Vascugel ® 58 lomitapide 58 SIMPADICO 58 Torisel 58 DEB# 58 bevacizumab Avastin ® 58 CUSTOM III 58 galiximab 58 Proxinium TM 58 LCP AtorFen 58 Oral NKTR 58 degarelix 58 Phase 2b Clinical Trial 58 Lucentis monotherapy 58 PSN# [002] 58 INCB# [002] 58 ARIKACE 58 achieved CCyR 58 systemically administered 58 MADIT II 58 trodusquemine 58 AEG# 58 PRADAXA #mg 58 Enzastaurin 58 BRAF V#E mutation 58 Aurexis 58 mg dose 58 virological suppression 58 FOLFOX6 58 dose escalation 58 IOP lowering 58 peginterferon alfa 2a 58 TELINTRA 58 multicentre randomized 58 pharmacokinetic characteristics 58 randomized multicenter 58 Ataluren 58 Edge STudy 58 BCIRG 58 Relapsed Multiple Myeloma 58 GEM OS2 58 coronary stenting 58 lacosamide 58 lumbar spine BMD 58 Antitumor Activity 58 preoperative chemotherapy 58 relapsed multiple myeloma 58 zalutumumab 58 GVAX 58 RhuDex 58 metastatic hormone refractory 58 remission CR 58 androgen deprivation 58 analgesic efficacy 58 PRADAXA 58 EGS# 58 Nesiritide 58 low dose cytarabine 58 dose limiting toxicities 58 cerebrovascular events 58 PreCISe study 58 AGILECT ® 58 radiolabeled TM# 58 Phase 2b trial 58 subcutaneous PRO 58 STX# 58 paclitaxel cisplatin 58 EDSS score 58 JAK Inhibitor 58 microbiological eradication 58 multicenter phase 58 adjuvant radiation 58 MoxDuo TM IR 58 evaluable 58 CLIRS 58 CALGB # [002] 58 receptor tyrosine kinase inhibitor 58 Solid Tumors 58 glatiramer acetate 58 noninfectious uveitis 58 glycated hemoglobin HbA1c 58 SUCCEED trial 58 oral Hycamtin 58 Diamyd ® 58 dobutamine 58 acyclovir Lauriad R 58 Vimpat R 58 Bosentan 58 PEG interferon 58 #mg QD [002] 58 plasma uric acid 58 MACCE 58 EMBLEM TM 58 pharmacodynamic parameters 58 midstage clinical 58 AIR CF2 58 MIRAPEX 58 annualized relapse 58 relapsed ALL 58 Genz # 58 leukemia AML 58 otelixizumab 58 LPV r 58 Zemplar Capsules 58 Azixa 58 steroid dexamethasone 58 relapsed AML 58 estramustine 58 PREZISTA r arm 58 EORTC 58 PFO closure 58 HSCT 58 HGS ETR2 58 metastatic malignant melanoma 58 HbA1c levels 58 perampanel 58 lamivudine refractory patients 57 dyskinesia PD LID 57 concurrent chemoradiation 57 evaluable patients 57 rALLy trial 57 dimebon 57 olaparib 57 prospective multicentre 57 complete remissions 57 resected pancreatic cancer 57 decompensated heart failure 57 RECIST criteria 57 ELND# 57 Solid Tumors criteria 57 proliferative diabetic retinopathy 57 nerve conduction velocity 57 dapagliflozin 57 HF ACTION 57 LymphoStat B 57 metastatic CRC 57 ORENCIA ® 57 ritonavir boosted 57 gout flares 57 NAbs 57 darunavir r 57 APPRAISE 57 octreotide 57 davunetide 57 PREZISTA rtv 57 oral prodrug 57 refractory gout 57 Phase 1b 57 events AEs 57 AA Amyloidosis 57 Dapagliflozin 57 melphalan prednisone 57 TYSABRI natalizumab 57 guanfacine extended release 57 RAPAFLO R 57 paclitaxel Taxol R 57 varespladib 57 baseline A1C 57 elevated ALT 57 DOXIL 57 multiple ascending dose 57 ASA# 57 Phase 2b randomized 57 RGB # 57 colorectal cancer liver metastases 57 romidepsin 57 coronary revascularization 57 subgroup analyzes 57 Neupro R 57 HBeAg positive patients 57 RECORD1 57 temsirolimus 57 Rasagiline 57 rALLy clinical trial 57 antitumor activity 57 aprepitant 57 retinal vein occlusion 57 heavily pretreated 57 cobiprostone 57 TLUS 57 tumor shrinkage 57 octreotide LAR 57 IFN beta 57 tecarfarin 57 STN stimulation 57 multicenter trials 57 FAMPYRA 57 miglustat 57 Octreolin 57 TLK# 57 XmAb# 57 ALN TTR# 57 Temsirolimus 57 thetreatment 57 flavopiridol 57 macroalbuminuria 57 ENDEAVOR IV 57 Tasimelteon 57 pharmacodynamic profile 57 transfemoral 57 administered subcutaneously 57 Lupuzor ™ 57 doxorubicin cyclophosphamide 57 PROSTVAC VF 57 relapsing remitting MS RRMS 57 AEGR 57 heavily pretreated patients 57 PCI ExTRACT TIMI 57 oral antidiabetic medication 57 CombAT 57 AZX# 57 tesmilifene 57 fasting plasma glucose 57 CRESTOR #mg 57 oral methylnaltrexone 57 follicular NHL 57 non squamous histology 57 confirmatory Phase III 57 ciclesonide 57 Fulvestrant 57 liposomal formulation 57 genotypic resistance 57 ExTRACT TIMI 57 neratinib 57 VA# [002] 57 pradefovir 57 seroprotection 57 idraparinux 57 MoxDuo 57 dose cytarabine 57 pharmacodynamic 57 Telbivudine 57 Dupuytren Contracture 57 multicenter prospective 57 GetGoal Phase III 57 azacytidine 57 urinary N telopeptide 57 Epratuzumab 57 Combo Stent 57 dexmedetomidine 57 unresectable stage 57 opioid induced bowel dysfunction 57 ACE inhibitor ramipril 57 Q#IR 57 colorectal liver metastases